Biocartis is a commercial-stage, small-cap molecular diagnostics (MDx) company listed on Euronext (ticker: BCART) since April 2015. We develop highly innovative diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform, launched in September 2014, is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting.
Our main value driver is our menu of rapid, easy and highly accurate molecular diagnostics tests, focused on oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. In June 2016, we were active in over 50 countries and had close to 300 Idylla™ platforms installed at clients worldwide.